Bringing radiotheranostics
to the world
Our mission is to enhance worldwide patient access to targeted theranostics through the generator-produced radioisotopes: Rhenium-188 and Technetium-99m
Technology
Harnessing the power and versatility of Rhenium-188
to deliver radiotherapies to the world.
Rhenium-188 is a powerful beta-emitting isotope long regarded as an attractive candidate for targeted radionuclide therapy in cancer. Because it can be produced using an on-site generator, Rhenium-188 enables a highly differentiated solution for regions with limited radiopharmacy infrastructure or dispersed populations.
A high-energy (2.12 KeV) beta-emission, maximising damage to the tumour cells
A short half-life of 16.9 hours, suited to the pharmacokinetics of small-molecule delivery systems
Shared chemistry with technetium-99m, the workhorse of nuclear medicine imaging around the world
Ability to be produced from a 188-W (tungsten)-based generator.
Leveraging generator technology
Radiopharmaceuticals based on more common therapeutic radioisotopes (on market or in development) such as lutetium-177 (177Lu) and actinium-225 (225Ac), are typically centrally manufactured in facilities that require significant investment and infrastructure to operate, such as reactors or cyclotrons. By contrast, a generator is a convenient system for on-site production of some commonly-used radionuclides.
Pipeline
An advanced pipeline of targeted radiopharmaceuticals designed to maximise access worldwide.
PSMA
CTN under filing
Our story
Rhine Pharma is a product of a research collaboration between Telix and the Heidelberg University Hospital.
In 2021, Telix and Heidelberg University Hospital commenced a collaboration to develop a next-generation theranostic for urologic oncology. The aim was to develop a PSMA-targeting small molecule that could be labelled with either 99mTc for SPECT imaging, or 188Re for radioligand therapy.
The collaboration was successful, with our first compound (RHN001) being discovered and patented. The intellectual property was spun out into a newly-formed company called Rhine Pharma GmbH, with our original German collaborators joining as Rhine’s inaugural Scientific Advisory Board.
In parallel, Rhine Pharma is working with Professor Mike Sathekge and his team at NuMeRI, University of Pretoria, South Africa to initiate a Phase I/II clinical trial of RHN001-Dx and RHN001-Tx called the RHINO trial.
The RHINO trial has received approval from the South African Health Products Regulatory Authority (SAHPRA) and ethics committee approval and is expected to dose its first patient in Q1 2025.
Partners
Rhine Pharma is supported by a global network of institutions and organisations striving to make radiopharmaceuticals available to patients all over the world.
NuMeRI
Oncidium Foundation
Telix Pharmaceuticals
Oncobeta GmbH
Team
Jonathan Barlow
Senior Advisor
Frederik Giesel
Scientific Advisory Board
Jens Cardinale
Scientific Advisory Board
Clemens Kratochwil
Scientific Advisory Board
Ken Herrmann
Scientific Advisory Board
News
Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and rhenium-188 (188Re).
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic oncology…
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
Telix today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021…
JNM Publication from July 2023
Prostate-specific membrane antigen (PSMA) theranostics have been introduced with 68Ga and 177Lu, the most used radionuclides…
Get in Touch
©2024 Rhine Pharma